A carregar...
AAI101, a Novel β-Lactamase Inhibitor: Microbiological and Enzymatic Profiling
BACKGROUND: AAI101 is a novel β-lactamase inhibitor (BLI), active against ESBLs and other β-lactamases. AAI101 combined with cefepime (FEP) is in Phase 2 clinical trials. The objective of this study was to determine differences between AAI101 and tazobactam in their inhibition of selected β-lactamas...
Na minha lista:
| Publicado no: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5631055/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.924 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|